29 January 2021 - 08:38 The Novavax vaccine being tested in SA has demonstrated not only high clinical efficacy against the virus that causes Covid-19, but also significant clinical effectiveness against both the rapidly emerging South African and UK variants. Image: 123RF/David Izquierdo Roger
The Novavax vaccine has demonstrated not only high clinical efficacy against the prototype SARS-CoV-2, the virus that causes Covid-19, but also significant clinical effectiveness against both the rapidly emerging South African and UK variants.
This was revealed by the Vaccines and Infectious Diseases Analytics Research Unit (Vida) at Wits University on Thursday.
It said in the SA Phase 2b clinical trial, 60% efficacy for the prevention of mild, moderate and severe Covid-19 disease was observed in the 94% of the study population that was HIV negative. The phase 2b is the safety and efficacy study of the vaccine.
Latest - Novavax Covid-19 vaccine the first to demonstrate clinical efficacy against South African variant wits.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wits.ac.za Daily Mail and Mail on Sunday newspapers.
Novavax vaccine protects against COVID-19, but is less effective against South African strain upi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upi.com Daily Mail and Mail on Sunday newspapers.
Source:
Streetwise Reports (1/29/21) Novavax Inc. shares established a new 52-week high after the firm s COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.
Biotechnology company Novavax Inc. (NVAX:NASDAQ), which is focused on developing next-generation vaccines to address serious infectious diseases, yesterday announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (U.K.).
The firm advised that the study was conducted during the time when COVID-19 transmission was high and a new U.K. variant strain of the virus had emerged and begun to circulate widely. Novavax stated the Phase 3 trial was carried out in partnership with the U.K. Government s Vaccines Taskforce. The company added that it also obtained succ